ZAP Surgical Systems Announces Chairman of Foxconn Technology Joins Board of Directors

Appointment Demonstrates Foxconn and ZAP Co-Founder Terry Guo’s Commitment to Accelerated Commercialization of ZAP-X Non-Invasive Brain Tumor Treatment Platform

ZAP Surgical Systems, Inc., developer and manufacturer of the ZAP-X® surgical robot for non-invasive ablation of brain tumors, today announced that the Chairman of Foxconn Technology Co Ltd, Lu Jun-Fu (Stanley Lu), has joined the ZAP Surgical Board of Directors.

“I am thrilled to welcome Stanley Lu to our Board of Directors where he will join us in our common quest to treat and transform the lives of millions of patients each year by means of the ZAP-X surgical robot,” said Dr. John R. Adler, MD, Stanford Professor of Neurosurgery and founder & Chief Executive Officer of ZAP Surgical Systems. “At ZAP we have developed the next-generation platform for non-invasively treating brain cancer. Unfortunately, more than 4 million people each year suffer from brain, head & neck cancers and are not being treated optimally with existing radiosurgical solutions. ZAP’s singular goal is to meet this challenge.”

Stanley Lu is the Chairman of Foxconn Technology Co Ltd, elected in October 2021. Stanley received an EMBA from the Chinese University of Hong Kong and an EMBA from the National Sun Yat-sen University. Prior, Stanley was the Chief Financial Officer and spokesperson of Foxsemicon Integrated Technology Inc.

Terry Guo, founder and former Chairman and Chief Executive Officer of Foxconn, co-founded ZAP Surgical in 2014, and contributed entrepreneurial expertise and his anchor investment established ZAP Surgical as an independent company. Prior to the company’s inception, the ZAP-X platform was developed within and spun out from Varian Medical Systems, now a Siemens Healthineers company.

In addition to Foxconn and Siemens Healthineers, ZAP investors include Primavera Capital Group, Chow Tai Fook Enterprises, GT Healthcare Capital Partners, ShangBay Capital, and Hogy Medical.

Hot this week

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution